Development of Low-Intensity Focused Ultrasound for Post Traumatic Brain Injury Depression
Key facts
- Who runs it
- Stanford University
- Where
- Stanford, United StatesSee the site
- Trial code
- Status
- Not yet recruiting
- People taking part
- 25 people, planned
- Started
- 1 Nov 2026
- Expected to end
- 31 Dec 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Active Low-Intensity Focused Ultrasound (LIFU)
- Sham Low-Intensity Focused Ultrasound (LIFU)
- Record updated
- 18 September 2026
Who can take part
- Age
- 22 years to 55 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (26)Hide the full registry criteria
Who can take part
- Adult Veteran, male or female, 22 to 55 years of age at the time of screening
- Able to read, understand, and provide written, dated informed consent before initiation of formal study screening procedures. A brief IRB-approved telephone pre-screen may be conducted prior to written informed consent as described in Section 8.1. Proficiency in English sufficient to complete questionnaires / follow instructions during fMRI assessments and LIFU interventions. Stated willingness to comply with all study procedures, including availability for the duration of the study, and to communicate with study personnel about adverse events and other clinically important information
- History of non-penetrating mild to moderate TBI confirmed by medical records and adjudicated by the study investigator using established TBI criteria (e.g., ACRM/VA-DoD criteria). If contemporaneous records are incomplete, a structured lifetime TBI interview may be used to support classification
- The TBI must have occurred at least 3 months before the occurrence of depression
- Current depressive disorder defined in the Diagnosis and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5)
- Medical records confirming a history of moderate to severe treatment-resistance as defined by a score of 7-14 on the Maudsley Staging Method (MSM3)
- MADRS score of ≥20 at screening
- Total duration of current depressive episode is less than 2 years
- LIFU naive
- Access to ongoing psychiatric care before and after completion of the study
- The dose of the primary antidepressant medication must be stable for 6 weeks prior to baseline , and participants must agree to continue at this dose throughout the study period
- In good general health, as evidenced by medical history
- For females of reproductive potential: use of highly effective contraception for at least 1 month prior to baseline and agreement to use such a method during study participation
- Agreement to adhere to Lifestyle Considerations (see section 5.3) throughout study duration
Who cannot take part
- Any lifetime DSM-5 depressive disorder or clinically significant depressive episode with onset prior to the qualifying index TBI, including major depressive disorder, persistent depressive disorder, or other specified/unspecified depressive disorder, or any antidepressant treatment initiated for depression prior to the index TBI
- Any history of ECT without meeting responder criteria 11. Recent (within 4 weeks of any clinical effect) or concurrent use of rapid acting antidepressant agent (i.e., ketamine or a course of ECT) 12. History of significant neurologic disease, including dementia, Parkinson's or Huntington's disease, brain tumor, seizure disorder, subdural hematoma, or multiple sclerosis 13. Untreated or insufficiently treated endocrine disorder. 14. Contraindication to receiving LIFU 15. Contraindication to MRI (ferromagnetic metal in their body) 16. Treatment with another investigational drug or other intervention within the study period 17. Unstable symptoms between screening and baseline as defined by a > 30% change in MADRS-S score
- Primary psychiatric condition other than MDD requiring treatment except stable comorbid anxiety disorder
- History of or current psychotic disorder or bipolar disorder
- Severe borderline personality disorder
- Diagnosis of Intellectual Disability or Autism Spectrum Disorder
- Current moderate or severe substance use disorder or demonstrating signs of acute substance withdrawal
- Cognitive impairment (defined as MoCA < 23)
- Any other condition deemed by the PD to interfere with the study or increase risk to the participant
- Pregnancy
- Urine screening test positive for illicit substances
- Active suicidal ideation (defined as an MSSI > 8) or a suicide attempt (as defined by the C-SSRS) within the past one year
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Post-traumatic brain injury depression or veteran health
Where in United States
- Department of Psychiatry and Behavioral Sciences, Stanford School of MedicineStanford, United StatesContact: Nick Bassano, MSWNot yet recruiting
About the trial
What the trial wants to find out
The goal of this clinical trial is to learn about evaluate the safety, tolerability, and feasibility of MRI-guided LIFU targeting the sgACC in Veterans with post-traumatic brain injury depression. The main questions it aims to answer are:
Read full original descriptionShow less
1. the safety, tolerability, and feasibility of MRI-guided LIFU. 2. Evaluate preliminary antidepressant efficacy. 3. Characterize target engagement using multimodal neuroimaging and electrophysiology. 4. Identify imaging and electrophysiological biomarkers that predict treatment response. 5. Generate preliminary effect size estimates to support future multicenter clinical trials.
The 2 groups in the trial
- Active Low-Intensity Focused Ultrasound (LIFU)Existing treatment, for comparison
Participants receive active LIFU over 5 consecutive treatment days, with 5 sessions per day and 20 minutes per session
- Sham Low-Intensity Focused Ultrasound (LIFU)Sham treatment, for comparison
Participants receive sham LIFU over 5 consecutive treatment days, with 5 sessions per day and 20 minutes per session
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Criteria questions
- Built from NCT07828483, who can take part
- Record updated
- 18 September 2026